| Clinical insights into novel immune checkpoint inhibitors JB Lee, SJ Ha, HR Kim Frontiers in Pharmacology 12, 681320, 2021 | 98 | 2021 |
| Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy JB Lee, HR Kim, SJ Ha Immune Network 22 (1), 2022 | 74 | 2022 |
| Role and function of O-GlcNAcylation in cancer JB Lee, KH Pyo, HR Kim Cancers 13 (21), 5365, 2021 | 48 | 2021 |
| Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer HS Park, WS Kwon, S Park, E Jo, SJ Lim, C Lee, JB Lee, M Jung, HS Kim, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 28 | 2019 |
| Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations JB Lee, M Jung, SH Beom, GM Kim, HR Kim, HJ Choi, JH Sohn, JB Ahn, ... Investigational New Drugs 39, 1366-1374, 2021 | 21 | 2021 |
| Guidelines for cancer care during the COVID-19 pandemic in South Korea JB Lee, M Jung, JH Kim, BH Kim, Y Kim, YS Kim, BC Kim, J Kim, SH Moon, ... Cancer Research and Treatment: Official Journal of Korean Cancer Association …, 2021 | 19 | 2021 |
| Clinical perspectives to overcome acquired resistance to anti–programmed death-1 and anti–programmed death ligand-1 therapy in non-small cell lung cancer YJ Lee, JB Lee, SJ Ha, HR Kim Molecules and cells 44 (5), 363-373, 2021 | 16 | 2021 |
| Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma JB Lee, MH Hong, SY Park, S Chae, D Hwang, SJ Ha, HS Shim, HR Kim Scientific reports 11 (1), 8551, 2021 | 14 | 2021 |
| Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer JB Lee, KA Kim, HY Cho, DA Kim, WK Kim, D Yong, H Lee, SS Yoon, ... Scientific reports 11 (1), 20263, 2021 | 13 | 2021 |
| First-in-human phase I study of BVAC-B cell therapy in HER2-positive advanced gastric cancer. JB Lee, WS Kwon, HS Kim, M Jung, S Kim, M Park, W Kim, KY Choi, T Oh, ... Journal of Clinical Oncology 38 (15_suppl), 4534-4534, 2020 | 13 | 2020 |
| Patritumab Deruxtecan: Paving the Way for EGFR-TKI–Resistant NSCLC SM Lim, CG Kim, JB Lee, BC Cho Cancer Discovery 12 (1), 16-19, 2022 | 11 | 2022 |
| Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations JL Low, SM Lim, JB Lee, BC Cho, RA Soo Therapeutic Advances in Medical Oncology 15, 17588359221146131, 2023 | 10 | 2023 |
| Temsirolimus in Asian metastatic/recurrent non-clear cell renal carcinoma JB Lee, HS Park, S Park, HJ Lee, KA Kwon, YJ Choi, YJ Kim, CM Nam, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2019 | 9 | 2019 |
| Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter … JB Lee, HS Kim, I Jung, SJ Shin, SH Beom, JS Chang, WS Koom, TI Kim, ... Trials 21, 1-7, 2020 | 8 | 2020 |
| Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia Y Kim, TH Go, J Jang, JB Lee, ST Lim, KY Shim, JI Lee, JH Kong The Korean Journal of Internal Medicine 36 (6), 1450, 2021 | 7 | 2021 |
| Role of preoperative chemoradiotherapy in clinical stage II/III rectal cancer patients undergoing total mesorectal excision: a retrospective propensity score analysis JB Lee, HS Kim, A Ham, JS Chang, SJ Shin, SH Beom, WS Koom, T Kim, ... Frontiers in oncology 10, 609313, 2021 | 7 | 2021 |
| Incorporation of SKI-G-801, a novel AXL inhibitor, with anti-PD-1 plus chemotherapy improves anti-tumor activity and survival by enhancing T cell immunity W Lee, DK Kim, CB Synn, HK Lee, S Park, DS Jung, Y Choi, JH Kim, ... Frontiers in Oncology 12, 821391, 2022 | 6 | 2022 |
| Prognostic implications of PD-L1 expression in patients with angiosarcoma JB Lee, BC Ahn, SH Kim, YH Lee, JW Han, MK Jeon, SH Kim, HS Kim Future science OA 7 (5), FSO691, 2021 | 5 | 2021 |
| Path less Traveled: Targeting Rare Driver Oncogenes in Non–Small-Cell Lung Cancer SM Lim, JB Lee, Y Oya, J Nutzinger, R Soo JCO Oncology Practice 20 (1), 47-56, 2024 | 2 | 2024 |
| Management of HER2 alterations in non-small cell lung cancer–The past, present, and future J Nutzinger, JB Lee, JL Low, PL Chia, ST Wijaya, BC Cho, SM Lim, R Soo Lung Cancer, 107385, 2023 | 2 | 2023 |
